Mammalian target of rapamycin inhibitors in sarcomas

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Sarcomas are a rare malignancy accounting for less than 1% of all cancers diagnosed annually. Standard chemotherapy has a response rate of around 25% and newer agents are needed to improve the outcome in patients with advanced sarcomas. The mammalian target of rapamycin plays a central role in cell growth, proliferation, and apoptosis and its inhibition has demonstrated antitumor activity in many tumors and shows promise against sarcomas. RECENT FINDINGS: Recent studies of mammalian target of rapamycin inhibitors in sarcomas have demonstrated clinical benefit response in sarcomas. SUMMARY: Clinical benefit response uses standard Response Evaluation Criteria in Solid Tumors of complete response and partial response as well as stable disease lasting at least 4 months as an endpoint. This endpoint has been shown to select promising new agents against sarcomas. Using this endpoint, the use of the mammalian target of rapamycin inhibitor AP23573 has demonstrated activity against sarcomas. The use of the inhibitor RAD001 (everolimus) along with imatinib in patients with imatinib resistant gastrointestinal stromal tumor has shown promise. Future studies will need to be performed to determine the clinical differences among the mammalian target of rapamycin inhibitors in different subsets of sarcomas.

Original languageEnglish (US)
Pages (from-to)360-362
Number of pages3
JournalCurrent Opinion in Oncology
Volume18
Issue number4
DOIs
StatePublished - Jul 2006

Fingerprint

Sirolimus
Sarcoma
Neoplasms
Gastrointestinal Stromal Tumors
Cell Proliferation
Apoptosis
Drug Therapy
Growth

Keywords

  • AP23573
  • CCI-779
  • Clinical response benefit
  • mTOR
  • RAD001
  • Sarcoma

ASJC Scopus subject areas

  • Cancer Research

Cite this

Mammalian target of rapamycin inhibitors in sarcomas. / Okuno, Scott Heitaka.

In: Current Opinion in Oncology, Vol. 18, No. 4, 07.2006, p. 360-362.

Research output: Contribution to journalArticle

@article{ee39fcca7fce47859810b5cf8b36b7c1,
title = "Mammalian target of rapamycin inhibitors in sarcomas",
abstract = "PURPOSE OF REVIEW: Sarcomas are a rare malignancy accounting for less than 1{\%} of all cancers diagnosed annually. Standard chemotherapy has a response rate of around 25{\%} and newer agents are needed to improve the outcome in patients with advanced sarcomas. The mammalian target of rapamycin plays a central role in cell growth, proliferation, and apoptosis and its inhibition has demonstrated antitumor activity in many tumors and shows promise against sarcomas. RECENT FINDINGS: Recent studies of mammalian target of rapamycin inhibitors in sarcomas have demonstrated clinical benefit response in sarcomas. SUMMARY: Clinical benefit response uses standard Response Evaluation Criteria in Solid Tumors of complete response and partial response as well as stable disease lasting at least 4 months as an endpoint. This endpoint has been shown to select promising new agents against sarcomas. Using this endpoint, the use of the mammalian target of rapamycin inhibitor AP23573 has demonstrated activity against sarcomas. The use of the inhibitor RAD001 (everolimus) along with imatinib in patients with imatinib resistant gastrointestinal stromal tumor has shown promise. Future studies will need to be performed to determine the clinical differences among the mammalian target of rapamycin inhibitors in different subsets of sarcomas.",
keywords = "AP23573, CCI-779, Clinical response benefit, mTOR, RAD001, Sarcoma",
author = "Okuno, {Scott Heitaka}",
year = "2006",
month = "7",
doi = "10.1097/01.cco.0000228742.72165.cf",
language = "English (US)",
volume = "18",
pages = "360--362",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Mammalian target of rapamycin inhibitors in sarcomas

AU - Okuno, Scott Heitaka

PY - 2006/7

Y1 - 2006/7

N2 - PURPOSE OF REVIEW: Sarcomas are a rare malignancy accounting for less than 1% of all cancers diagnosed annually. Standard chemotherapy has a response rate of around 25% and newer agents are needed to improve the outcome in patients with advanced sarcomas. The mammalian target of rapamycin plays a central role in cell growth, proliferation, and apoptosis and its inhibition has demonstrated antitumor activity in many tumors and shows promise against sarcomas. RECENT FINDINGS: Recent studies of mammalian target of rapamycin inhibitors in sarcomas have demonstrated clinical benefit response in sarcomas. SUMMARY: Clinical benefit response uses standard Response Evaluation Criteria in Solid Tumors of complete response and partial response as well as stable disease lasting at least 4 months as an endpoint. This endpoint has been shown to select promising new agents against sarcomas. Using this endpoint, the use of the mammalian target of rapamycin inhibitor AP23573 has demonstrated activity against sarcomas. The use of the inhibitor RAD001 (everolimus) along with imatinib in patients with imatinib resistant gastrointestinal stromal tumor has shown promise. Future studies will need to be performed to determine the clinical differences among the mammalian target of rapamycin inhibitors in different subsets of sarcomas.

AB - PURPOSE OF REVIEW: Sarcomas are a rare malignancy accounting for less than 1% of all cancers diagnosed annually. Standard chemotherapy has a response rate of around 25% and newer agents are needed to improve the outcome in patients with advanced sarcomas. The mammalian target of rapamycin plays a central role in cell growth, proliferation, and apoptosis and its inhibition has demonstrated antitumor activity in many tumors and shows promise against sarcomas. RECENT FINDINGS: Recent studies of mammalian target of rapamycin inhibitors in sarcomas have demonstrated clinical benefit response in sarcomas. SUMMARY: Clinical benefit response uses standard Response Evaluation Criteria in Solid Tumors of complete response and partial response as well as stable disease lasting at least 4 months as an endpoint. This endpoint has been shown to select promising new agents against sarcomas. Using this endpoint, the use of the mammalian target of rapamycin inhibitor AP23573 has demonstrated activity against sarcomas. The use of the inhibitor RAD001 (everolimus) along with imatinib in patients with imatinib resistant gastrointestinal stromal tumor has shown promise. Future studies will need to be performed to determine the clinical differences among the mammalian target of rapamycin inhibitors in different subsets of sarcomas.

KW - AP23573

KW - CCI-779

KW - Clinical response benefit

KW - mTOR

KW - RAD001

KW - Sarcoma

UR - http://www.scopus.com/inward/record.url?scp=33748088144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748088144&partnerID=8YFLogxK

U2 - 10.1097/01.cco.0000228742.72165.cf

DO - 10.1097/01.cco.0000228742.72165.cf

M3 - Article

C2 - 16721131

AN - SCOPUS:33748088144

VL - 18

SP - 360

EP - 362

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 4

ER -